Tracking macrophages by direct and indirect 89Zr PET imaging
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07752-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Vittorio De Santis und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, London, SE1 7EH, UK. Hauptthemen laut MEDLINE: Zirconium, Positron-Emission Tomography, Radioisotopes, Macrophages. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council, Wellcome Trust, Cancer Research UK.
Abstract (Originalsprache)
PURPOSE: Tumour-associated macrophages are highly abundant in the tumour microenvironment, and their levels influence tumour progression and therapy response. Tracking macrophages by positron-emission tomography (PET) can yield critical information on the dynamics of macrophage infiltration, particularly in diseases such as breast cancer, in which tumour-associated macrophages are significant in the evolution of the tumour microenvironment. METHODS: Two complementary PET imaging methods were used to track macrophages. The first method used a novel [89Zr]Zr-labelled antibody that targets the murine F4/80 receptor, which is located on the cell surface of in situ macrophages. [89Zr]Zr-DFO-anti-F4/80 and a non-specific [89Zr]Zr-labelled control antibody were developed and characterised for their specificity. The second method involved directly labelling mouse-derived macrophages with [89Zr]Zr-oxine, and the effect of [89Zr]Zr-radiolabelling on macrophage viability and phenotype was evaluated. Using PET imaging and ex vivo tissue counting, the in vivo biodistribution of [89Zr]Zr-DFO-anti-F4/80 and [89Zr]Zr-labelled murine macrophages was quantified in female BALB/c mice bearing syngeneic, orthotopic 4T1 breast cancer tumours. RESULTS: [89Zr]Zr-DFO-anti-F4/80 showed target-specific uptake in vitro. At a dose of 100 μg DFO-anti-F4/80 per mouse, [89Zr]Zr-DFO-anti-F4/80 enabled visualization of tumour-resident macrophages by PET/CT with high contrast. This was not observed for non-specific [89Zr]Zr-DFO-IgG2b. PET/CT imaging showed that intravenously administered [89Zr]Zr-labelled M0 macrophages migrated to the liver and spleen, with a proportion of macrophages trafficking to the tumour. [89Zr]Zr-oxine labelling did not affect macrophage viability nor phenotype, even at an absorbed radiation dose of 3.31 Gy. CONCLUSION: For the first time, we have applied and compared two complementary PET/CT imaging strategies to quantify the infiltration of macrophages in an orthotopic, syngeneic murine model of breast cancer. First, PET/CT imaging using an “indirect” cell tracking approach with a new [89Zr]Zr-DFO-anti-F4/80 antibody radiotracer showed that resident tumour-associated macrophages are abundant in this syngeneic breast cancer model. Second, PET/CT imaging using [89Zr]Zr-labelled M0 macrophages showed that macrophages in the blood pool migrate to the tumour, within 24 h. These tools have utility in quantifying macrophage distribution and migration in cancer, particularly in the context of new and existing therapies in which macrophage populations are perturbed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, London, SE1 7EH, UK.
- Division of Breast Cancer Research, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK.
- GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK.
- Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, London, SE1 7EH, UK. samantha.terry@kcl.ac.uk.
ORCID-Profile: Samantha Y A Terry
Förderung
- Engineering and Physical Sciences Research Council
- Wellcome Trust
- Cancer Research UK
- Medical Research Council
- GlaxoSmithKline foundation
Zitieren
APA
De Santis, V., Flaherty, R., Banu, A., Gape, P., Langdon, S., Rigby, A., Mishra, A., Firth, G., Pham, T. T., Carrascal-Miniño, A., Kim, J., Sunassee, K., Cleveland, M., De Rosales, R. T. M., Witney, T. H., Ma, M. T., & Terry, S. Y. A. (2026). Tracking macrophages by direct and indirect 89Zr PET imaging. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07752-8
Vancouver
De Santis V, Flaherty R, Banu A, Gape P, Langdon S, Rigby A, et al. Tracking macrophages by direct and indirect 89Zr PET imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07752-8
BibTeX
@article{DeSantis2026,
author = {De Santis, Vittorio and Flaherty, Renee and Banu, Arshiya and Gape, Paul and Langdon, Sophie and Rigby, Alex and Mishra, Aishwarya and Firth, George and Pham, Truc T and Carrascal-Miniño, Amaia and Kim, Jana and Sunassee, Kavitha and Cleveland, Matthew and De Rosales, Rafael T M and Witney, Timothy H and Ma, Michelle T and Terry, Samantha Y A},
title = {Tracking macrophages by direct and indirect 89Zr PET imaging},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07752-8}
}
EUVIMED